<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545866</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0064</org_study_id>
    <secondary_id>UG1HD034216</secondary_id>
    <secondary_id>UG1HD027904</secondary_id>
    <secondary_id>UG1HD021364</secondary_id>
    <secondary_id>UG1HD027853</secondary_id>
    <secondary_id>UG1HD040689</secondary_id>
    <secondary_id>UG1HD040492</secondary_id>
    <secondary_id>UG1HD027851</secondary_id>
    <secondary_id>UG1HD087229</secondary_id>
    <secondary_id>UG1HD053109</secondary_id>
    <secondary_id>UG1HD068278</secondary_id>
    <secondary_id>UG1HD068244</secondary_id>
    <secondary_id>UG1HD068263</secondary_id>
    <secondary_id>UG1HD027880</secondary_id>
    <secondary_id>UG1HD053089</secondary_id>
    <secondary_id>UG1HD087226</secondary_id>
    <secondary_id>U10HD036790</secondary_id>
    <nct_id>NCT04545866</nct_id>
  </id_info>
  <brief_title>The Budesonide in Babies (BiB) Trial</brief_title>
  <acronym>BiB</acronym>
  <official_title>Randomized Controlled Trial of Budesonide + Surfactant Versus Surfactant Alone in Extremely Preterm Infants (&quot;The Budesonide in Babies (BiB) Trial&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Neonatal Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Neonatal Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, masked, active-controlled, multicenter trial designed to&#xD;
      determine whether early intratracheal administration of a combination of budesonide with&#xD;
      surfactant, as compared to surfactant alone, will reduce the incidence of physiologic&#xD;
      bronchopulmonary dysplasia (BPD) or death by 36 weeks' post-menstrual age in extremely&#xD;
      preterm infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From a study of 9575 extremely preterm (22-28 weeks gestational age and 401-1500g birth&#xD;
      weight) infants born between 2003 and 2007 and enrolled in the Eunice Kennedy Shriver&#xD;
      National Institute of Child Health and Human Development (NICHD) Neonatal Research Network&#xD;
      (NRN), it is anticipated that 93% of extremely preterm infants will develop respiratory&#xD;
      distress syndrome, 68% will develop bronchopulmonary dysplasia (BPD), 16% will develop severe&#xD;
      intraventricular hemorrhage, and 36% will develop late-onset sepsis (PMID: 20732945).&#xD;
      Furthermore, in 2014 20% of the infants enrolled in the NRN Generic Database (GDB) died (8%&#xD;
      by less than 12 hours, 12% between 12 hours and 120 days, and 1% after 120 days) and 47% of&#xD;
      infants who survived to 36 weeks' post-menstrual age (PMA) developed physiologic BPD (NRN GDB&#xD;
      data). BPD is therefore one of the most common morbidities in extremely preterm infants.&#xD;
      Death is a competing outcome for BPD, as infants who die before ascertainment of BPD at 36&#xD;
      weeks' PMA cannot be diagnosed with BPD even though they may have been at the highest risk.&#xD;
      As children get older, BPD has been shown to be associated with worse cognitive outcomes in&#xD;
      school age and with abnormal pulmonary function in adolescence and adulthood (PMID: 14595077;&#xD;
      15499947; 2247118).&#xD;
&#xD;
      Recent randomized trials have indicated a lower incidence of BPD/death with the use of a&#xD;
      combination of budesonide with surfactant (budesonide + surfactant) compared to surfactant&#xD;
      alone when administered soon after birth. Therefore, after obtaining informed consent and&#xD;
      confirming eligibility for the trial, infants are randomized in a 1:1 allocation ratio to&#xD;
      either the budesonide + surfactant arm or the surfactant alone arm within 48 hours of birth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The investigator, primary providers, primary data collectors, and participants will be masked to randomization arm assignment. Only research pharmacists and a designated respiratory therapist (or other qualified person) will be unmasked at the enrolling sites. The designated respiratory therapist (or other qualified person) must be unmasked to allow drug mixing at bedside for expeditious study drug administration; however, this person will not be the primary medical provider nor the primary data collector for that infant, and will not be otherwise involved in the research.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Physiologic BPD or death</measure>
    <time_frame>Randomization to 36 weeks' post-menstrual age</time_frame>
    <description>Physiologic BPD or death by 36 weeks' PMA. Physiologic BPD is determined using existing NRN GDB criteria at 36 weeks' PMA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Death by 36 weeks' post-menstrual age</measure>
    <time_frame>Randomization to 36 weeks' post-menstrual age</time_frame>
    <description>Death by 36 weeks' PMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Physiologic BPD</measure>
    <time_frame>36 weeks' post-menstrual age</time_frame>
    <description>Physiologic BPD as determined by existing NRN GDB criteria at 36 weeks' PMA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of BPD Severity</measure>
    <time_frame>36 weeks' post-menstrual age</time_frame>
    <description>BPD severity is defined as in Jensen et al. (2019; PMID: 30995069) at 36 weeks' PMA according to treatment with the following respiratory support:&#xD;
No BPD: room air;&#xD;
Grade 1: nasal cannula at flow rates â‰¤ 2 L/min;&#xD;
Grade 2: nasal cannula at flow rates &gt; 2 L/min or noninvasive positive airway pressure;&#xD;
Grade 3: invasive mechanical ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Grade 3 BPD</measure>
    <time_frame>36 weeks' post-menstrual age</time_frame>
    <description>Grade 3 BPD at 36 weeks' PMA according to the Jensen et al. (2019 PMID: 30995069) definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Use of Additional Postnatal Steroids</measure>
    <time_frame>7 days post final dose of study drug through 36 weeks' post-menstrual age</time_frame>
    <description>Use of postnatal steroids for treatment of evolving chronic lung disease (separate from study drug) from 7 days after the final dose of study drug through 36 weeks' PMA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Severe Neurodevelopmental Impairment (NDI)</measure>
    <time_frame>22-26 months corrected age</time_frame>
    <description>Severe NDI is assessed at the 2-year follow-up (22-26 months corrected age). In light of the upcoming transition to BSID IV, severe NDI assessment will be based on the agreed upon definition at the time of the first participant's follow-up assessment. An example of such a definition could be presence of any of the following:&#xD;
Cognitive composite score on the BSID IV &lt; 70,&#xD;
GMFCS level 3-5,&#xD;
Severe hearing impairment (no functional hearing despite amplification), or&#xD;
Bilateral severe visual impairment (bilateral blindness despite correction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Death by 2 years</measure>
    <time_frame>Randomization to 22-26 months corrected age</time_frame>
    <description>Death by 2-year follow-up (22-26 months corrected age)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Severe NDI or death</measure>
    <time_frame>Randomization to 22-26 months corrected age</time_frame>
    <description>Severe NDI or death as assessed at 2-year follow-up (22-26 months corrected age)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1160</enrollment>
  <condition>Bronchopulmonary Dysplasia (BPD)</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>Prematurity; Extreme</condition>
  <condition>Neonatal</condition>
  <arm_group>
    <arm_group_label>budesonide with surfactant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants randomized to the intervention arm receive a dose of surfactant (poractant alfa; Curosurf) mixed with budesonide (Pulmicort nebulizing suspension) within 50 hours of birth and administered via endotracheal tube.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>surfactant alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants randomized to the active control arm receive a dose of surfactant (poractant alfa; Curosurf).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide (Pulmicort nebulizing suspension).</intervention_name>
    <description>The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.</description>
    <arm_group_label>budesonide with surfactant</arm_group_label>
    <other_name>Pulmicort nebulizing suspension.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>surfactant (poractant alfa;Curosurf)</intervention_name>
    <description>The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.</description>
    <arm_group_label>surfactant alone</arm_group_label>
    <other_name>poractant alfa;Curosurf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liveborn infants 22 0/7 - 28 6/7 weeks gestation or 401 - 1000 grams (inclusive) birth&#xD;
             weight&#xD;
&#xD;
          -  Clinical decision to give surfactant&#xD;
&#xD;
          -  Less than or equal to 48 hours postnatal age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Terminal illness (heart rate &lt; 100 beats per minute, unresponsiveness to&#xD;
             resuscitation) or unlikely to survive as judged by the clinician&#xD;
&#xD;
          -  Decision to redirect or limit support&#xD;
&#xD;
          -  Use of surfactant before enrollment (first dose of surfactant must be study drug)&#xD;
&#xD;
          -  Infant received systemic steroids prior to enrollment&#xD;
&#xD;
          -  Use of indomethacin, either received by the mother within 24 hours prior to&#xD;
             delivery,received by the infant prior to enrollment, or intent to administer to the&#xD;
             infant for IVH prophylaxis or PDA management from enrollment up to 7 days of final&#xD;
             dose of study drug&#xD;
&#xD;
          -  Serious chromosomal abnormalities or major malformations&#xD;
&#xD;
          -  Known congenital infections including, but not limited to, confirmed sepsis,&#xD;
             congenital CMV, etc.&#xD;
&#xD;
          -  Infants with a permanent neuromuscular condition that affects respiration&#xD;
&#xD;
          -  Enrollment in a conflicting clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Namasivayam Ambalavanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Namasivayam Ambalavanan, MD</last_name>
    <phone>(205) 934 4680</phone>
    <email>ambal@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abhik Das, PhD</last_name>
    <phone>301-230-4640</phone>
    <email>adas@rti.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-7335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Namasivayam A. Ambalavanan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Waldemar Carlo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krisa P Van Meurs, MD</last_name>
    </contact>
    <investigator>
      <last_name>Krisa P Van Meurs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ravi Patel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brenda Poindexter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravi Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward F Bell, MD</last_name>
    </contact>
    <investigator>
      <last_name>Edward F Bell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi L Watterberg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kristi L Watterberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl T D'Angio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carl T D'Angio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RTI International</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. Michael Cotten, MD</last_name>
    </contact>
    <investigator>
      <last_name>C. Michael Cotten, MD MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Merhar, MD MS</last_name>
    </contact>
    <investigator>
      <last_name>Vivek Narendran, MD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Merhar, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University, Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Maria C. Hibbs, MD, MSCE</last_name>
    </contact>
    <investigator>
      <last_name>Deanne C. Wilson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Maria C. Hibbs, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Sanchez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pablo Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Eichenwald, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Eichenwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University - Women and Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abbot R. Laptook, MD</last_name>
    </contact>
    <investigator>
      <last_name>Abbot R Laptook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myra Wyckoff, MD</last_name>
    </contact>
    <investigator>
      <last_name>Myra Wyckoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jon E Tyson, MD MPH</last_name>
    </contact>
    <investigator>
      <last_name>Jon E. Tyson, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Ohls, MD</last_name>
    </contact>
    <investigator>
      <last_name>Robin Ohls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2020</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Poractant alfa</mesh_term>
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NIH has had a long-standing policy to share and make available to the public the results and accomplishments of the activities that it funds. The NRN plans to share de-identified data after final publication in an NIH supported data repository such as the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

